POLARIS INSIGHTS

Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance

(TLX), a commercial-stage company, reported a 19% increase in group revenue.

Read the full account of the story

More from Markets · Back to Polaris Insights